It sits in a comparison page where the details that matter most are access, cost, clinical fit, and what a licensed clinician should confirm and should help with comparison and decision support

GLP-1 Key Research Facts Full name: Glucagon-Like Peptide-1 incretin hormone of the proglucagon family Primary bioactive form: GLP-1(736)amide 30 amino acids, C-terminally amidated Gene source: Proglucagon gene processed by PCSK1 in intestinal L-cells and brainstem NTS neurons In vivo half-life: Approximately 12 minutes rapidly inactivated by DPP-4 (cleaves His7-Ala8 dipeptide) Primary receptor: GLP-1R (GLP-1 receptor) class B G protein-coupled receptor (GPCR) Signalling: GLP-1R activation cAMP elevation PKA/CREB activation glucose-dependent insulin secretion Additional signalling: PI3K/Akt pathway -cell survival, proliferation, and glucose sensitivity Secretion pattern: Biphasic post-meal release from intestinal L-cells early neural/endocrine peak + late direct nutrient-contact peak Fasting plasma level: ~510 pmol/L
Weight gain is a common occurrence during menopause and often an unwelcome one
Prior weight loss drugs were unpleasant (rimonabant), ineffective (Contrave), or dangerous (methamphetamine, fen-phen, 2,4-DNP)
For bloating, water helps move gas through the intestines more efficiently
Thinner patients or people with less abdominal fat are at slightly higher risk of accidentally hitting muscle